Cargando…

Risk factors and a prognostic model for patients with borderline resectable locally advanced T3–4N0–1 non-small cell lung cancer: a population-based study

BACKGROUND: Non-small cell lung cancer (NSCLC) is a malignant disease with a significant morbidity rate. For patients diagnosed with borderline resectable locally advanced (T3–4 invasion and N0–1) NSCLC, the optimal treatment and prognosis are still under debate. This study aimed to develop a predic...

Descripción completa

Detalles Bibliográficos
Autores principales:	Liu, Yi, Lai, Hongjin, Zhang, Ren, Xia, Liang, Guo, Chenglin, Liu, Lunxu
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	AME Publishing Company 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10643965/ https://www.ncbi.nlm.nih.gov/pubmed/37969361 http://dx.doi.org/10.21037/tcr-23-519

Ejemplares similares

Does surgical margin affect recurrence and survival after sublobar pulmonary resection for lung cancer?
por: Liu, Weijing, et al.
Publicado: (2021)

Prognostic Factors for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer Receiving Neoadjuvant FOLFIRINOX
por: Choi, Young Hoon, et al.
Publicado: (2021)

The borderline resectable and locally advanced pancreatic ductal adenocarcinoma: Definition
por: Soweid, Assaad M.
Publicado: (2017)

FOLFIRINOX in borderline resectable and locally advanced unresectable pancreatic adenocarcinoma
por: Yoo, Changhoon, et al.
Publicado: (2020)

The borderline resectable/locally advanced pancreatic ductal adenocarcinoma: EUS oriented
por: Iordache, Sevastiţa, et al.
Publicado: (2017)

Neoadjuvant Chemotherapy Switch in Borderline Resectable/Locally Advanced Pancreatic Cancer
por: Alva-Ruiz, Roberto, et al.
Publicado: (2021)

Advances and Remaining Challenges in the Treatment for Borderline Resectable and Locally Advanced Pancreatic Ductal Adenocarcinoma
por: Sulciner, Megan L., et al.
Publicado: (2022)

Ipilimumab plus nivolumab and chemoradiotherapy followed by surgery in patients with resectable and borderline resectable T3-4N0–1 non-small cell lung cancer: the INCREASE trial
por: Dickhoff, Chris, et al.
Publicado: (2020)

Gemcitabine plus nab-paclitaxel for locally advanced or borderline resectable pancreatic cancer
por: Tsujimoto, Akiko, et al.
Publicado: (2019)

The borderline resectable/locally advanced pancreatic ductal adenocarcinoma: What should be the surgeon's choice?
por: Zerbi, Alessandro, et al.
Publicado: (2017)

Neoadjuvant chemotherapy and radiotherapy outcomes in borderline‐resectable and locally‐advanced pancreatic cancer patients
por: Botta, Gregory P., et al.
Publicado: (2022)

ASO Author Reflections: Chemotherapy Regimen in Borderline Resectable and Locally Advanced Pancreatic Cancer—Resection Cuts the Deal
por: Eshmuminov, Dilmurodjon, et al.
Publicado: (2023)

Synchronous resection of 12 small pulmonary nodules guided by a noninvasive 3D printed emulation model: A case report
por: Li, Kaidi, et al.
Publicado: (2022)

Prognostic impact of tumor-associated macrophage infiltration in non-small cell lung cancer: A systemic review and meta-analysis
por: Mei, Jiandong, et al.
Publicado: (2016)

Completely Resected N0 Non-Small Cell Lung Cancer: Prognostic Factors Affecting Long-Term Survival
por: Tantraworasin, Apichat, et al.
Publicado: (2013)

Development and validation of prognostic nomogram for T(1-3)N(0)M(0) non-small cell lung cancer after curative resection
por: Mei, Weijian, et al.
Publicado: (2023)

A retrospective study of neoadjuvant FOLFIRINOX in unresectable or borderline-resectable locally advanced pancreatic adenocarcinoma
por: Hosein, Peter J, et al.
Publicado: (2012)

Opinions and use of neoadjuvant therapy for resectable, borderline resectable, and locally advanced pancreatic cancer: international survey and case-vignette study
por: Heinrich, Stefan, et al.
Publicado: (2019)

Pathologic response with neoadjuvant chemotherapy and stereotactic body radiotherapy for borderline resectable and locally-advanced pancreatic cancer
por: Rajagopalan, Malolan S, et al.
Publicado: (2013)

The borderline resectable/locally advanced pancreatic ductal adenocarcinoma staging with computed tomography/magnetic resonance imaging
por: D’Onofrio, Mirko, et al.
Publicado: (2017)

Neoadjuvant FOLFIRINOX for Patients with Borderline Resectable or Locally Advanced Pancreatic Cancer: Results of a Decision Analysis
por: Choi, Jin G., et al.
Publicado: (2018)

Predictive factors for survival in borderline resectable and locally advanced pancreatic cancer: are these really two different entities?
por: de Carvalho, Luís Filipe Abreu, et al.
Publicado: (2023)

Evaluation of Preoperative Hematologic Markers as Prognostic Factors and Establishment of Novel Risk Stratification in Resected pN0 Non-Small-Cell Lung Cancer
por: Zhang, Tiehong, et al.
Publicado: (2014)

The Timing of Surgery Following Stereotactic Body Radiation Therapy Impacts Local Control for Borderline Resectable or Locally Advanced Pancreatic Cancer
por: Lin, Timothy, et al.
Publicado: (2023)

Survival outcome and prognostic factors of neoadjuvant treatment followed by resection for borderline resectable pancreatic cancer
por: Kim, Hyeong Seok, et al.
Publicado: (2017)

The Number of Resected Lymph Nodes (nLNs) Combined with Tumor Size as a Prognostic Factor in Patients with Pathologic N0 and Nx Non-Small Cell Lung Cancer
por: Yang, Miaomiao, et al.
Publicado: (2013)

Neoadjuvant Chemotherapy in Locally Advanced and Borderline Resectable Nonsquamous Sinonasal Tumors (Esthesioneuroblastoma and Sinonasal Tumor with Neuroendocrine Differentiation)
por: Patil, Vijay M., et al.
Publicado: (2016)

Erratum: The borderline resectable/locally advanced pancreatic ductal adenocarcinoma staging with computed tomography/magnetic resonance imaging
Publicado: (2018)

Prognostic value of neoadjuvant therapy for resectable and borderline resectable pancreatic cancer: A meta-analysis of randomized controlled trials
por: Liu, Shangtong, et al.
Publicado: (2023)

Survival outcome after stereotactic body radiotherapy for locally advanced and borderline resectable pancreatic cancer: A systematic review and meta-analysis
por: Liu, Shi, et al.
Publicado: (2021)

RNSCLC-PRSP software to predict the prognostic risk and survival in patients with resected T(1-3)N(0–2) M(0) non-small cell lung cancer
por: Zhang, Yunkui, et al.
Publicado: (2019)

Lung cancer mimicking aortic dissecting aneurysm in a patient with situs inversus totalis
por: Lin, Feng, et al.
Publicado: (2015)

Successful resection of a huge mediastinal liposarcoma extended to the bilateral thorax
por: Lin, Feng, et al.
Publicado: (2015)

Naples Prognostic Score as an Independent Predictor of Survival Outcomes for Resected Locally Advanced Non-Small Cell Lung Cancer Patients After Neoadjuvant Treatment
por: Zou, Zhonghua, et al.
Publicado: (2023)

Phase II study of induction chemotherapy followed by chemoradiotherapy in patients with borderline resectable and unresectable locally advanced pancreatic cancer
por: Fiore, Michele, et al.
Publicado: (2017)

Neoadjuvant treatment for locally advanced unresectable and borderline resectable pancreatic cancer: oncological outcomes at a single academic centre
por: Roselló, Susana, et al.
Publicado: (2020)

Proper adjuvant therapy in patients with borderline resectable and locally advanced pancreatic cancer who had received neoadjuvant FOLFIRINOX
por: Choi, Jin Ho, et al.
Publicado: (2022)

Reduced and Normalized Carbohydrate Antigen 19-9 Concentrations after Neoadjuvant Chemotherapy Have Comparable Prognostic Performance in Patients with Borderline Resectable and Locally Advanced Pancreatic Cancer
por: Lee, Woohyung, et al.
Publicado: (2020)

Lung adenocarcinoma initially mimicking localized emphysema
por: Cheng, Jiahan, et al.
Publicado: (2020)

Network meta-analysis comparing neoadjuvant chemoradiation, neoadjuvant chemotherapy and upfront surgery in patients with resectable, borderline resectable, and locally advanced pancreatic ductal adenocarcinoma
por: Hu, Qiancheng, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_pbd26vdjgpjaaiouh8mvsn5las